NDAORALCAPSULE
Approved
Jul 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
TIGAN (trimethobenzamide hydrochloride) by Pfizer is 12. First approved in 1974.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TIGAN (trimethobenzamide HCl) is a small-molecule antiemetic approved in 1974 that acts on the chemoreceptor trigger zone in the medulla to prevent nausea and vomiting. The exact mechanism remains incompletely understood, but animal studies show it inhibits emetic responses to certain stimuli while offering limited protection against others. It is available as an oral capsule with a 7-9 hour elimination half-life and primarily used in palliative and post-operative settings.
LOE Approaching
Product is nearing loss of exclusivity with minimal linked positions; team is likely focused on lifecycle extension or managed decline.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of trimethobenzamide as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center…
Worked on TIGAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.